Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells

Comparative study with glibenclamide

Hiroshi Hirose, H. Maruyama, Y. Seto, K. Ito, T. Fujita, K. Dan, N. Kanda, T. Saruta, R. Kato

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We have reported that N-[(trans-4-isopropyl-cyclohexyl)-carbonyl]-D-phenylalanine (A-4166) stimulates insulin secretion in animal studies. To further elucidate the mechanisms underlying the actions of this agent, we investigated the effects of A-4166 on insulin and glucagon secretion with or without diazoxide, an ATP-sensitive potassium channel opener, using isolated perfused rat pancreas preparations, and compared the results with those of glibenclamide. Both 30 μmol/l A-4166 and 3 μmol glibenclamide significantly stimulated insulin secretion and reduced glucagon secretion to similar levels at a glucose concentration of 5.6 mmol/l (p < 0.01 for both vs, basal levels). After infusion of A-4166 was stopped, insulin levels promptly returned to the basal values, while insulin levels increased further even after discontinuation of glibenclamide. Furthermore, 100 μmol diazoxide significantly inhibited the insulin-stimulatory effects of both 30 μmol/l A-4166 and 3 μmol/l glibenclamide (p < 0.05 and p < 0.01, respectively). However, the effects of diazoxide on glucagon secretion differed between the two groups; 30 μmol/l A-4166 produced a transient increase in glucagon secretion (p < 0.05 vs. basal levels) but 3 μmol/l glibenclamide suppressed glucagon secretion further (p < 0.01 vs. without diazoxide) with concomitant administration of 100 μmol/l diazoxide. These findings suggest that A-4166 directly stimulates insulin secretion, at least in part, through mechanisms resembling those of sulfonylurea, but exerts different effect on glucagon secretion in isolated perfused rat pancreas.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalPharmacology
Volume50
Issue number3
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

nateglinide
Glyburide
Phenylalanine
Hypoglycemic Agents
Diazoxide
Glucagon
Insulin
Pancreas
KATP Channels

Keywords

  • Blood glucose-lowering agents
  • Glucagon
  • Insulin
  • Isolated perfused rat pancreas

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells : Comparative study with glibenclamide. / Hirose, Hiroshi; Maruyama, H.; Seto, Y.; Ito, K.; Fujita, T.; Dan, K.; Kanda, N.; Saruta, T.; Kato, R.

In: Pharmacology, Vol. 50, No. 3, 1995, p. 175-181.

Research output: Contribution to journalArticle

Hirose, H, Maruyama, H, Seto, Y, Ito, K, Fujita, T, Dan, K, Kanda, N, Saruta, T & Kato, R 1995, 'Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells: Comparative study with glibenclamide', Pharmacology, vol. 50, no. 3, pp. 175-181.
Hirose, Hiroshi ; Maruyama, H. ; Seto, Y. ; Ito, K. ; Fujita, T. ; Dan, K. ; Kanda, N. ; Saruta, T. ; Kato, R. / Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells : Comparative study with glibenclamide. In: Pharmacology. 1995 ; Vol. 50, No. 3. pp. 175-181.
@article{c11f916d04a047db9573c5bb68ad0955,
title = "Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells: Comparative study with glibenclamide",
abstract = "We have reported that N-[(trans-4-isopropyl-cyclohexyl)-carbonyl]-D-phenylalanine (A-4166) stimulates insulin secretion in animal studies. To further elucidate the mechanisms underlying the actions of this agent, we investigated the effects of A-4166 on insulin and glucagon secretion with or without diazoxide, an ATP-sensitive potassium channel opener, using isolated perfused rat pancreas preparations, and compared the results with those of glibenclamide. Both 30 μmol/l A-4166 and 3 μmol glibenclamide significantly stimulated insulin secretion and reduced glucagon secretion to similar levels at a glucose concentration of 5.6 mmol/l (p < 0.01 for both vs, basal levels). After infusion of A-4166 was stopped, insulin levels promptly returned to the basal values, while insulin levels increased further even after discontinuation of glibenclamide. Furthermore, 100 μmol diazoxide significantly inhibited the insulin-stimulatory effects of both 30 μmol/l A-4166 and 3 μmol/l glibenclamide (p < 0.05 and p < 0.01, respectively). However, the effects of diazoxide on glucagon secretion differed between the two groups; 30 μmol/l A-4166 produced a transient increase in glucagon secretion (p < 0.05 vs. basal levels) but 3 μmol/l glibenclamide suppressed glucagon secretion further (p < 0.01 vs. without diazoxide) with concomitant administration of 100 μmol/l diazoxide. These findings suggest that A-4166 directly stimulates insulin secretion, at least in part, through mechanisms resembling those of sulfonylurea, but exerts different effect on glucagon secretion in isolated perfused rat pancreas.",
keywords = "Blood glucose-lowering agents, Glucagon, Insulin, Isolated perfused rat pancreas",
author = "Hiroshi Hirose and H. Maruyama and Y. Seto and K. Ito and T. Fujita and K. Dan and N. Kanda and T. Saruta and R. Kato",
year = "1995",
language = "English",
volume = "50",
pages = "175--181",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Effects of D-Phenylalanine-Derivative hypoglycemic agent a-4166 on pancreatic α- and β-Cells

T2 - Comparative study with glibenclamide

AU - Hirose, Hiroshi

AU - Maruyama, H.

AU - Seto, Y.

AU - Ito, K.

AU - Fujita, T.

AU - Dan, K.

AU - Kanda, N.

AU - Saruta, T.

AU - Kato, R.

PY - 1995

Y1 - 1995

N2 - We have reported that N-[(trans-4-isopropyl-cyclohexyl)-carbonyl]-D-phenylalanine (A-4166) stimulates insulin secretion in animal studies. To further elucidate the mechanisms underlying the actions of this agent, we investigated the effects of A-4166 on insulin and glucagon secretion with or without diazoxide, an ATP-sensitive potassium channel opener, using isolated perfused rat pancreas preparations, and compared the results with those of glibenclamide. Both 30 μmol/l A-4166 and 3 μmol glibenclamide significantly stimulated insulin secretion and reduced glucagon secretion to similar levels at a glucose concentration of 5.6 mmol/l (p < 0.01 for both vs, basal levels). After infusion of A-4166 was stopped, insulin levels promptly returned to the basal values, while insulin levels increased further even after discontinuation of glibenclamide. Furthermore, 100 μmol diazoxide significantly inhibited the insulin-stimulatory effects of both 30 μmol/l A-4166 and 3 μmol/l glibenclamide (p < 0.05 and p < 0.01, respectively). However, the effects of diazoxide on glucagon secretion differed between the two groups; 30 μmol/l A-4166 produced a transient increase in glucagon secretion (p < 0.05 vs. basal levels) but 3 μmol/l glibenclamide suppressed glucagon secretion further (p < 0.01 vs. without diazoxide) with concomitant administration of 100 μmol/l diazoxide. These findings suggest that A-4166 directly stimulates insulin secretion, at least in part, through mechanisms resembling those of sulfonylurea, but exerts different effect on glucagon secretion in isolated perfused rat pancreas.

AB - We have reported that N-[(trans-4-isopropyl-cyclohexyl)-carbonyl]-D-phenylalanine (A-4166) stimulates insulin secretion in animal studies. To further elucidate the mechanisms underlying the actions of this agent, we investigated the effects of A-4166 on insulin and glucagon secretion with or without diazoxide, an ATP-sensitive potassium channel opener, using isolated perfused rat pancreas preparations, and compared the results with those of glibenclamide. Both 30 μmol/l A-4166 and 3 μmol glibenclamide significantly stimulated insulin secretion and reduced glucagon secretion to similar levels at a glucose concentration of 5.6 mmol/l (p < 0.01 for both vs, basal levels). After infusion of A-4166 was stopped, insulin levels promptly returned to the basal values, while insulin levels increased further even after discontinuation of glibenclamide. Furthermore, 100 μmol diazoxide significantly inhibited the insulin-stimulatory effects of both 30 μmol/l A-4166 and 3 μmol/l glibenclamide (p < 0.05 and p < 0.01, respectively). However, the effects of diazoxide on glucagon secretion differed between the two groups; 30 μmol/l A-4166 produced a transient increase in glucagon secretion (p < 0.05 vs. basal levels) but 3 μmol/l glibenclamide suppressed glucagon secretion further (p < 0.01 vs. without diazoxide) with concomitant administration of 100 μmol/l diazoxide. These findings suggest that A-4166 directly stimulates insulin secretion, at least in part, through mechanisms resembling those of sulfonylurea, but exerts different effect on glucagon secretion in isolated perfused rat pancreas.

KW - Blood glucose-lowering agents

KW - Glucagon

KW - Insulin

KW - Isolated perfused rat pancreas

UR - http://www.scopus.com/inward/record.url?scp=0028953155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028953155&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 175

EP - 181

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3

ER -